APA (7th ed.) Citation

AH, B., M, L., AM, R., D, B., W, A., S, S., . . . M, M. (2024). Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Cancer, 130(18), 3123. https://doi.org/10.1002/cncr.35365

Chicago Style (17th ed.) Citation

AH, Bazarbachi, et al. "Posttransplant Cyclophosphamide Versus Anti-thymocyte Globulin Versus Combination for Graft-versus-host Disease Prevention in Haploidentical Transplantation for Adult Acute Myeloid Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party." Cancer 130, no. 18 (2024): 3123. https://doi.org/10.1002/cncr.35365.

MLA (9th ed.) Citation

AH, Bazarbachi, et al. "Posttransplant Cyclophosphamide Versus Anti-thymocyte Globulin Versus Combination for Graft-versus-host Disease Prevention in Haploidentical Transplantation for Adult Acute Myeloid Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party." Cancer, vol. 130, no. 18, 2024, p. 3123, https://doi.org/10.1002/cncr.35365.